Guides / GLP-1 dosing

Can you stay on a GLP-1 dose longer than 4 weeks?

The labels set a shortest time on each dose, not a longest. A few also say what to do when a dose is hard to tolerate.

By PeptideTracker editorial team · Updated November 8, 2026 · 10 sources

[00] Short answer

  1. Most GLP-1 dose increases come "after at least 4 weeks" on the current dose. That sets a minimum, so staying longer fits the wording1–4.
  2. Wegovy (US): "If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks."1
  3. Wegovy (UK): with significant stomach symptoms, "consider delaying dose escalation or lowering to the previous dose until symptoms have improved"7.
  4. Zepbound: "If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage." Maintenance doses are 5, 10 or 15 mg2.
  5. Mounjaro and Ozempic: going up is for when more blood sugar control "is needed", so the labels don't require every step3–4.

Can you stay on a GLP-1 dose longer than 4 weeks?

Yes, by the wording. Zepbound, Mounjaro and Ozempic allow each later increase only after at least 4 weeks on the current dose, so 4 weeks is a minimum, and Wegovy's label suggests delaying a step if a dose isn't tolerated1–4. Whether you go up, stay or go down is decided with your prescriber.

How long each dose step lasts, in each US label's own words (section 2)
MedicineExact wording on time per stepWording on staying longer or going down
Wegovy injection (semaglutide)0.25, 0.5, 1 and 1.7 mg over weeks 1 to 16, then maintenance from week 17. 7.2 mg only "for patients who tolerate the 2.4 mg dosage for at least 4 weeks"1"If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks."1
Zepbound (tirzepatide)2.5 mg "for 4 weeks", then 5 mg. Further 2.5 mg steps "after at least 4 weeks on the current dose"2"If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage."2
Mounjaro (tirzepatide)"If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose."3No tolerability wording in section 2. Each increase depends on whether more control is needed3
Ozempic (semaglutide)"After 4 weeks on the 0.25 mg dosage, increase the dosage to 0.5 mg." Then 1 mg and 2 mg if more control is needed "after at least 4 weeks"4No tolerability wording in section 2. Maintenance is 0.5, 1 or 2 mg "based on glycemic control"4
Trulicity (dulaglutide)0.75 mg, then 1.5 mg "after 4 weeks". Further 1.5 mg steps "after at least 4 weeks on the current dosage"5Increases are "for additional glycemic control"5
Foundayo (orforglipron), daily tabletEach step "after at least 30 days". Steps above 5.5 mg are "based on treatment response and tolerability"6No wording on going back down

The titration planner lays out these steps as dates. It uses the label minimum for each step, and you can treat any step as lasting longer.

[Tool]Plan your dose stepsLabel schedules for Mounjaro, Zepbound, Wegovy and Ozempic

What do the labels say if you can't tolerate a GLP-1 dose?

Among the weekly injections, Wegovy and Zepbound are the two labels with clear tolerability wording. Wegovy (US) says to consider delaying the next increase by 4 weeks, and Zepbound says to consider a lower maintenance dose1–2.

  • Wegovy injection (US): "consider delaying dosage escalation for 4 weeks". For the maintenance dose, "Consider treatment response and tolerability": 1.7 mg or 2.4 mg for weight reduction in adults1.
  • Wegovy for MASH (US): "If patients do not tolerate the maintenance dosage of 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly. Consider reescalation to 2.4 mg once weekly."1
  • Wegovy tablets (US): "If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation." No set length is given1.
  • Wegovy (UK): "In case of significant gastrointestinal symptoms, consider delaying dose escalation or lowering to the previous dose until symptoms have improved."7
  • Zepbound: "Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage."2

The Mounjaro and Ozempic US labels don't mention tolerability in their dosing sections. They make each increase depend on whether more blood sugar control is needed3–4. Side effects by drug are in our GLP-1 side effects guide.

Is the starting dose different from the later steps?

Yes, in several labels. The first step is written as a fixed 4 weeks and isn't a maintenance dose. The "at least 4 weeks" wording applies to the steps after it2,4,8–9.

Starting dose wording: fixed first step, and whether it counts as a maintenance dose
MedicineFirst step on the labelMaintenance doses named
Zepbound2.5 mg "for 4 weeks". "The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage."25, 10 or 15 mg for weight. 10 or 15 mg for sleep apnea2
Mounjaro (UK)"After 4 weeks, the dose should be increased to 5 mg once weekly."85, 10 and 15 mg for adults8
Ozempic"After 4 weeks on the 0.25 mg dosage, increase the dosage to 0.5 mg." The UK SmPC adds: "Semaglutide 0.25 mg is not a maintenance dose."4,90.5, 1 or 2 mg4
Wegovy injection0.25 mg for weeks 1 to 411.7 or 2.4 mg for adult weight reduction, up to 7.2 mg in the US1

The US Mounjaro label doesn't name maintenance doses. It gives a 2.5 mg start and a 15 mg maximum for adults3. Full schedules are in our tirzepatide dosage chart and semaglutide dosage chart.

UK: the 6-month check on Wegovy and Mounjaro

The UK Wegovy and Mounjaro SmPCs add a review point for weight management. If you haven't lost at least 5% of your starting weight, they say a decision on whether to continue is needed7–8.

  • Wegovy (UK): "If patients have been unable to lose at least 5% of their initial body weight after 6 months on treatment, a decision is required on whether to continue treatment."7
  • Mounjaro (UK): the 6 months count from reaching the highest dose you tolerate: "6 months after titrating to the highest tolerated dose"8.

The UK Wegovy SmPC also says the 7.2 mg dose, for weight management in adults with obesity, can follow "a minimum of 4 weeks on the 2.4 mg dose"7. More on that step is in our Wegovy 7.2 mg guide.

Questions

Can I stay on 2.5 mg of Mounjaro or Zepbound for longer than 4 weeks?

The Zepbound label says 2.5 mg is for 4 weeks to start treatment and isn't approved as a maintenance dose. The UK Mounjaro SmPC also says to go up to 5 mg after 4 weeks. If you're struggling with 2.5 mg, talk to your prescriber.

Can I stay on Wegovy 1 mg instead of going up?

The US label says that if a dose isn't tolerated during the increases, consider delaying the next step for 4 weeks. It names 1.7 mg and 2.4 mg as the maintenance doses for adult weight reduction. Your prescriber decides with you.

Can I go back down a dose on Zepbound?

The Zepbound label says that if a maintenance dose isn't tolerated, consider a lower maintenance dose. Maintenance doses for weight are 5, 10 or 15 mg.

Do I have to keep going up on Ozempic?

No. The Ozempic label says maintenance is 0.5, 1 or 2 mg based on blood sugar control, and each step above 0.5 mg is for when more control is needed, after at least 4 weeks on the current dose.

Does staying on a dose longer mean I'm doing it wrong?

No. The labels set a minimum time on each step, not a maximum. Wegovy's label suggests delaying a step if a dose isn't tolerated, and the UK Wegovy SmPC allows going back to the previous dose until stomach symptoms improve.

Sources

Checked against US prescribing information for Wegovy, Zepbound, Mounjaro, Ozempic, Trulicity and Foundayo (2026), and the UK SmPCs for Wegovy, Mounjaro and Ozempic. How we check

  1. 1Wegovy (semaglutide) injection and tablets: US prescribing information, Novo Nordisk. sections 2.2 and 2.3, Table 1, revised 06/2026
  2. 2Zepbound (tirzepatide): US prescribing information, Eli Lilly. sections 2.1 and 2.2, revised 08/2026
  3. 3Mounjaro (tirzepatide): US prescribing information, Eli Lilly. section 2.1, revised 08/2026
  4. 4Ozempic (semaglutide) injection: US prescribing information, Novo Nordisk. section 2.2, revised 05/2026
  5. 5Trulicity (dulaglutide): US prescribing information, Eli Lilly. section 2.1, revised 03/2026
  6. 6Foundayo (orforglipron) tablets: US prescribing information, Eli Lilly. section 2.1, revised 07/2026
  7. 7Wegovy FlexTouch solution for injection: UK SmPC. section 4.2, revised 09/2026
  8. 8Mounjaro KwikPen solution for injection: UK SmPC. section 4.2, revised 29 Aug 2026
  9. 9Ozempic solution for injection: UK SmPC. section 4.2, revised 07/2026
  10. 10Mounjaro KwikPen: UK patient leaflet. section 3, emc updated 3 Sep 2026

This guide explains what labels and published studies say. It isn't medical advice and doesn't replace your prescriber or pharmacist.

Spotted a mistake or something out of date? Tell us. We aim to fix factual errors within two working days.